# aTYR PHARMA INC: financial statements, quarterly

ATYR · Nasdaq · CIK 1339970 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/atyr.md) · [Financials](/companies/atyr/financials.md) · [Filings](/companies/atyr/filings.md) · [Insiders](/companies/atyr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/atyr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.4](/filings/0000950170-24-123305.md) | [0.0 d](/filings/0001339970-26-000008.md) | [0.2](/filings/0000950170-25-065640.md) | [0.0](/filings/0001339970-25-000009.md) | [0.0](/filings/0001193125-25-269587.md) | [0.0 d](/filings/0001339970-26-000008.md) | [0.0](/filings/0000950170-25-065640.md) | [0.0](/filings/0001339970-25-000009.md) | [0.2](/filings/0001193125-25-269587.md) | [0.0 d](/filings/0001339970-26-000008.md) | not reported | not reported |
| Research and development | $m | [10.3](/filings/0000950170-24-123305.md) | [12.8 d](/filings/0001339970-26-000008.md) | [13.4](/filings/0000950170-25-065640.md) | [14.0](/filings/0001339970-25-000009.md) | [14.8](/filings/0001193125-25-269587.md) | [12.2 d](/filings/0001339970-26-000008.md) | [11.8](/filings/0001339970-26-000033.md) | [15.4](/filings/0001339970-26-000053.md) | [22.1](/filings/0001193125-25-269587.md) | [10.9 d](/filings/0001339970-26-000008.md) | [7.3](/filings/0001339970-26-000033.md) | [6.7](/filings/0001339970-26-000053.md) |
| Operating income | $m | [(12.6)](/filings/0000950170-24-123305.md) | [(16.0) d](/filings/0001339970-26-000008.md) | [(16.6)](/filings/0000950170-25-065640.md) | [(17.3)](/filings/0001339970-25-000009.md) | [(18.1)](/filings/0001193125-25-269587.md) | [(15.8) d](/filings/0001339970-26-000008.md) | [(15.8)](/filings/0001339970-26-000033.md) | [(20.3)](/filings/0001339970-26-000053.md) | [(26.7)](/filings/0001193125-25-269587.md) | [(14.8) d](/filings/0001339970-26-000008.md) | [(11.4)](/filings/0001339970-26-000033.md) | [(10.9)](/filings/0001339970-26-000053.md) |
| Net income | $m | [(11.3)](/filings/0000950170-24-123305.md) | [(14.8) d](/filings/0001339970-26-000008.md) | [(15.5)](/filings/0000950170-25-065640.md) | [(16.3)](/filings/0001339970-25-000009.md) | [(17.3)](/filings/0001193125-25-269587.md) | [(15.0) d](/filings/0001339970-26-000008.md) | [(14.9)](/filings/0001339970-26-000033.md) | [(19.5)](/filings/0001339970-26-000053.md) | [(25.7)](/filings/0001193125-25-269587.md) | [(14.0) d](/filings/0001339970-26-000008.md) | [(10.8)](/filings/0001339970-26-000033.md) | [(10.3)](/filings/0001339970-26-000053.md) |
| Diluted EPS | $ per share | [(0.20)](/filings/0000950170-24-123305.md) | not reported | [(0.23)](/filings/0000950170-25-065640.md) | [(0.23)](/filings/0001339970-25-000009.md) | [(0.23)](/filings/0001193125-25-269587.md) | not reported | [(0.17)](/filings/0001339970-26-000033.md) | [(0.22)](/filings/0001339970-26-000053.md) | [(0.26)](/filings/0001193125-25-269587.md) | not reported | [(0.11)](/filings/0001339970-26-000033.md) | [(0.11)](/filings/0001339970-26-000053.md) |
| Basic EPS | $ per share | [(0.20)](/filings/0000950170-24-123305.md) | not reported | [(0.23)](/filings/0000950170-25-065640.md) | [(0.23)](/filings/0001339970-25-000009.md) | [(0.23)](/filings/0001193125-25-269587.md) | not reported | [(0.17)](/filings/0001339970-26-000033.md) | [(0.22)](/filings/0001339970-26-000053.md) | [(0.26)](/filings/0001193125-25-269587.md) | not reported | [(0.11)](/filings/0001339970-26-000033.md) | [(0.11)](/filings/0001339970-26-000053.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [9.8](/filings/0000950170-24-123305.md) | [22.5](/filings/0001339970-26-000008.md) | [6.8](/filings/0000950170-25-065640.md) | [6.8](/filings/0001339970-25-000009.md) | [11.5](/filings/0001193125-25-269587.md) | [11.1](/filings/0001339970-26-000008.md) | [10.4](/filings/0001339970-26-000033.md) | [17.2](/filings/0001339970-26-000053.md) | [6.2](/filings/0001193125-25-269587.md) | [10.7](/filings/0001339970-26-000053.md) | [10.0](/filings/0001339970-26-000033.md) | [16.2](/filings/0001339970-26-000053.md) |
| Current assets | $m | [107](/filings/0000950170-23-062058.md) | [103](/filings/0000950170-25-038888.md) | [96.9](/filings/0000950170-24-052092.md) | [90.3](/filings/0000950170-24-096185.md) | [76.3](/filings/0000950170-24-123305.md) | [82.0](/filings/0001339970-26-000008.md) | [83.3](/filings/0000950170-25-065640.md) | [87.5](/filings/0001339970-25-000009.md) | [93.0](/filings/0001193125-25-269587.md) | [80.2](/filings/0001339970-26-000053.md) | [67.6](/filings/0001339970-26-000033.md) | [58.4](/filings/0001339970-26-000053.md) |
| Total assets | $m | [125](/filings/0000950170-23-062058.md) | [121](/filings/0000950170-25-038888.md) | [113](/filings/0000950170-24-052092.md) | [106](/filings/0000950170-24-096185.md) | [91.6](/filings/0000950170-24-123305.md) | [96.8](/filings/0001339970-26-000008.md) | [97.2](/filings/0000950170-25-065640.md) | [102](/filings/0001339970-25-000009.md) | [107](/filings/0001193125-25-269587.md) | [93.0](/filings/0001339970-26-000053.md) | [79.7](/filings/0001339970-26-000033.md) | [69.8](/filings/0001339970-26-000053.md) |
| Current liabilities | $m | [12.9](/filings/0000950170-23-062058.md) | [16.4](/filings/0000950170-25-038888.md) | [16.0](/filings/0000950170-24-052092.md) | [11.8](/filings/0000950170-24-096185.md) | [14.1](/filings/0000950170-24-123305.md) | [15.0](/filings/0001339970-26-000008.md) | [10.7](/filings/0000950170-25-065640.md) | [15.5](/filings/0001339970-25-000009.md) | [15.7](/filings/0001193125-25-269587.md) | [15.1](/filings/0001339970-26-000053.md) | [11.7](/filings/0001339970-26-000033.md) | [11.4](/filings/0001339970-26-000053.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [98.4](/filings/0000950170-23-062058.md) | [90.7](/filings/0000950170-25-038888.md) | [84.5](/filings/0000950170-24-052092.md) | [81.6](/filings/0000950170-24-096185.md) | [65.3](/filings/0000950170-24-123305.md) | [70.0](/filings/0001339970-26-000008.md) | [75.1](/filings/0000950170-25-065640.md) | [74.8](/filings/0001339970-25-000009.md) | [80.2](/filings/0001193125-25-269587.md) | [67.5](/filings/0001339970-26-000053.md) | [57.9](/filings/0001339970-26-000033.md) | [48.8](/filings/0001339970-26-000053.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(9.6) d](/filings/0000950170-24-123305.md) | [(11.1) d](/filings/0001339970-26-000008.md) | [(22.4)](/filings/0000950170-25-065640.md) | [(20.4) d](/filings/0001339970-25-000009.md) | [(13.2) d](/filings/0001193125-25-269587.md) | [(13.1) d](/filings/0001339970-26-000008.md) | [(15.4)](/filings/0001339970-26-000033.md) | [(13.9) d](/filings/0001339970-26-000053.md) | [(20.5) d](/filings/0001193125-25-269587.md) | [(12.2) d](/filings/0001339970-26-000008.md) | [(12.5)](/filings/0001339970-26-000033.md) | [(9.4) d](/filings/0001339970-26-000053.md) |
| Capital expenditure | $m | [0.6 d](/filings/0000950170-24-123305.md) | [0.0 d](/filings/0001339970-26-000008.md) | [0.0](/filings/0000950170-25-065640.md) | [0.0 d](/filings/0001339970-25-000009.md) | [0.0 d](/filings/0001193125-25-269587.md) | [0.0 d](/filings/0001339970-26-000008.md) | [0.0](/filings/0001339970-26-000033.md) | [0.0 d](/filings/0001339970-26-000053.md) | [0.0 d](/filings/0001193125-25-269587.md) | [0.0 d](/filings/0001339970-26-000008.md) | [0.1](/filings/0001339970-26-000033.md) | [0.1 d](/filings/0001339970-26-000053.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [28.7](/filings/0000950170-23-062058.md) | [41.9](/filings/0000950170-24-052092.md) | [55.1](/filings/0000950170-24-096185.md) | [57.9](/filings/0000950170-24-123305.md) | [66.1](/filings/0000950170-25-065640.md) | [72.3](/filings/0001339970-25-000009.md) | [75.8](/filings/0001193125-25-269587.md) | [86.5](/filings/0001339970-26-000033.md) | [90.1](/filings/0001339970-26-000053.md) | [97.2](/filings/0001193125-25-269587.md) | [98.0](/filings/0001339970-26-000033.md) | [98.1](/filings/0001339970-26-000053.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 98,087,425 at 2026-07-31, from the cover of the [10-Q filed 2026-08-07](/filings/0001339970-26-000053.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.